Cargando…

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient

A durable response after the discontinuation of immune checkpoint-inhibitor therapy has previously been reported in several cancers. We herein describe a patient with gastric cancer who maintained a durable response after the discontinuation of nivolumab. A 65-year-old man was treated with nivolumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yatsuda, Yukino, Hirose, Suguru, Ito, Yoshimi, Onoda, Tsubasa, Sugiyama, Yutaro, Nagafuchi, Miho, Suzuki, Hirosumi, Niisato, Yusuke, Tange, Yoshitaka, Ikeda, Takafumi, Yamada, Takeshi, Yamamoto, Yoshiyuki, Ohyama Osawa, Mariko, Sakamoto, Noriaki, Moriwaki, Toshikazu, Mizokami, Yuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079905/ https://www.ncbi.nlm.nih.gov/pubmed/33162479 http://dx.doi.org/10.2169/internalmedicine.5893-20

Ejemplares similares

Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review
por: Hagiwara, Yuya, et al.
Publicado: (2022)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination
por: Matano, Daisuke, et al.
Publicado: (2017)

Sicca syndrome during ipilimumab and nivolumab therapy for metastatic renal cell carcinoma
por: Segawa, Takuya, et al.
Publicado: (2023)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Nakajima, Nobuyuki, et al.
Publicado: (2020)

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis
por: Ide, Maako, et al.
Publicado: (2018)

Remarkable antitumor effect of nivolumab in a patient with metastatic renal cell carcinoma previously treated with a peptide‐based vaccine
por: Kurahashi, Ryoma, et al.
Publicado: (2020)

Exercise training suppresses scavenger receptor CD36 expression in kupffer cells of nonalcoholic steatohepatitis model mice
por: Kawanishi, Noriaki, et al.
Publicado: (2018)

Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report
por: Lepir, Tanja, et al.
Publicado: (2019)

Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome–associated glioma
por: Cabezas-Camarero, Santiago, et al.
Publicado: (2022)

Usefulness of argon plasma coagulation for bleeding around hepaticojejunal anastomosis
por: Tange, Yoshitaka, et al.
Publicado: (2021)

Re: Long-term control in a patient with metastatic lung adenocarcinoma after discontinuation of nivolumab
por: Pampín-Sánchez, R, et al.
Publicado: (2021)

Exercise training attenuates neutrophil infiltration and elastase expression in adipose tissue of high-fat-diet-induced obese mice
por: Kawanishi, Noriaki, et al.
Publicado: (2015)

Macrophage depletion by clodronate liposome attenuates muscle injury and inflammation following exhaustive exercise
por: Kawanishi, Noriaki, et al.
Publicado: (2015)

Durable discontinuation of systemic therapy in patients affected by chronic graft-versus-host disease
por: Chen, George L., et al.
Publicado: (2022)

Durable discontinuation of systemic therapy for chronic graft-versus-host disease: myth or reality?
por: Pavletic, Steven Z., et al.
Publicado: (2022)

Adaptive Servo-ventilation Therapy Results in the Prevention of Arrhythmias in Patients with Heart Failure Due to Ischemic Heart Disease
por: Nagasaka, Takashi, et al.
Publicado: (2021)

Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report
por: Antoniou, Sofia, et al.
Publicado: (2021)

Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients
por: Jung, Young Kul, et al.
Publicado: (2011)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
por: Kim, Young Jip, et al.
Publicado: (2013)

Pathological complete response with nivolumab for recurrence of liver metastasis after gastrectomy of gastric cancer
por: Jun, Chen, et al.
Publicado: (2023)

Two primary cancers appeared after discontinuation of nivolumab in the course of treating Hodgkin lymphoma: a case report
por: Potluri, Lakshmi Bhavani, et al.
Publicado: (2023)

Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab
por: Schroeder, Brett A., et al.
Publicado: (2020)

Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden
por: Kang, Nai-Wen, et al.
Publicado: (2021)

Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort
por: Kaplan, Jess L., et al.
Publicado: (2023)

Editorial Comment from Dr Kojima to Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Kojima, Takahiro
Publicado: (2020)

Editorial Comment from Dr Yuasa to Possible abscopal effect after discontinuation of nivolumab in metastatic renal cell carcinoma
por: Yuasa, Takeshi
Publicado: (2020)

Relationship between the Incidence of Postoperative Fistula or Dysphagia and Resection Style, Gastric Tube Formation, and Irradiation following Free Jejunal Flap Transfer
por: Onoda, Satoshi, et al.
Publicado: (2020)

Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma
por: Billon, Emilien, et al.
Publicado: (2019)

Durable Remission in Hodgkin Lymphoma Treated With One Cycle of Bleomycin, Vinblastine, Dacarbazine and Two Doses of Nivolumab and Brentuximab Vedotin
por: Yohannan, Binoy, et al.
Publicado: (2022)

A durable complete response resulting from treatment with nivolumab plus ipilimumab for metastatic collecting duct carcinoma of the kidney
por: Funajima, Keisuke, et al.
Publicado: (2023)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

Two cases of delayed onset of immune‐related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer
por: Nakai, Yasutomo, et al.
Publicado: (2021)

Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab
por: Pasello, Giulia, et al.
Publicado: (2022)

Late Onset of Cardiac Metastasis of a Melanoma following Nivolumab Immunotherapy
por: Nakamura, Kenta, et al.
Publicado: (2022)

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature
por: Economides, Minas P., et al.
Publicado: (2020)

Neutrophil Depletion Attenuates Acute Liver Stress after Exhaustive Exercise in Mice
por: MIZOKAMI, TSUBASA, et al.
Publicado: (2023)

Durability of Bioprosthetic Valves in Patients on Dialysis
por: Uzuka, Takeshi, et al.
Publicado: (2022)

Resolution of Pruritus in a Child With Alagille Syndrome Treated With Maralixibat for Seven Years: Durable Response and Discontinuation of Other Medications
por: Garcia, Amy, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gjg167d5llmgeajltqlmsm9vbp